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Abstract 
Background 
Improving the quality of care for patients with vascular disease is a priority. Clinical 
guidance has emphasised the importance of early identification and active management of 
chronic kidney disease (CKD) in primary care in order to maintain vascular health. However, 
awareness of stage 3 CKD amongst patients remains limited. We aimed to identify predictors 
of patient self-report of CKD to inform tailoring of conversations around CKD in primary 
care for diverse patient populations. 
Methods 
We conducted a cross-sectional analysis of baseline data from 436 patients with stage 3 CKD 
from 24 GP practices taking part in a randomised controlled trial (RCT) evaluating a complex 
self-management intervention, which aimed to support the maintenance of vascular health in 
patients with stage 3 CKD. Potential predictors of patient self-report of CKD included 
demographics, stage of CKD, cardiovascular risk, self-reported co-morbidities, health status, 
self-management ability, and health service utilisation. 
Results 
Around half (52%, n =227) of patients did not self-report CKD. Self-report rates did not 
appreciably differ by practice. Multivariate analysis revealed that female patients (p = 0.003), 
and patients with stage 3b CKD (p < 0.001), and with higher anxiety levels (p < 0.001), were 
more likely to self-report CKD. 
Conclusions 
Self-report of kidney problems by patients on CKD registers was variable and patterned by 
sociodemographic factors. Although it cannot be assumed that failure to self-report indicates 
a lack of awareness of CKD, our data do suggest the need for greater consistency in 
discussions around kidney health, with meaningful and relevant clinical dialogue that is 
aligned with existing clinical encounters to enable shared decision making and minimise 
anxiety. 
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Background 
Chronic Kidney disease (CKD) is a growing public health concern. Clinical guidelines 
emphasise the importance of early identification and active management of CKD in 
maintaining vascular health in primary care [1]. This reflects evidence that CKD is an 
independent cardiovascular risk factor and that individuals with stable CKD are 
approximately 20 times more likely to die from cardiovascular disease than progress to end 
stage renal failure [2,3]. Recognising this risk, CKD has been incorporated into more recent 
cardiovascular risk calculators [4] and the introduction in 2006 of renal domains within the 
Quality and Outcomes Framework (QOF) (a UK pay-for-performance contract designed to 
improve quality of care) encourages regular monitoring of blood pressure for patients with 
stages 3 to 5 CKD (further detail in methods section below). [5]. Based upon best available 
evidence, indicators of quality have been assigned to a range of long-term conditions. 
General practices are then paid for delivering care in line with these QOF quality indicators. 
Nevertheless, there is evidence that the prevalence could be greater than that apparent in QOF 
CKD registers suggesting under-recognition in primary care [6]. 
The UK based national guidance NICE (National Institute for Health and Care Excellence) 
Quality Standards state that people with CKD are assessed for cardiovascular risk, and 
guidance highlights a need to offer information, education and lifestyle advice [1,3]. 
However, awareness of CKD among patients and practitioners is variable [7] and according 
to a recent UK based study, 41% of patients with stage 3 CKD were unaware of a CKD 
diagnosis as defined by self-report [8]. Moreover, the frequency of clinical discussion about 
CKD is considerably lower (26%) compared to discussions related to diabetes (60%), 
hypertension (72%) and medication adherence (89%) [9]. Improving the knowledge and 
personal skills of individuals with long-term conditions through shared decision-making is 
central to provision of self-management support in the UK [10-13]. A basic prerequisite for 
shared decision making and effective self-management education and support is awareness of 
a diagnosis [14]. 
Explanations for variation in the self-reporting of CKD may include considering reduced 
kidney function amongst older patients as a natural part of the ageing process [15,16]. 
Primary care professionals may be cautious not to over-diagnose CKD and have expressed 
concerns about the disclosure of CKD to patients [17,18], particularly around raising 
unnecessary anxiety in the elderly where clinical benefit was felt to be less certain [19]. 
Previous studies suggest that patients who are male and of younger age [8,16], who have 
CKD stage 3b with proteinuria [8,16,19], additional vascular risk factors [7,16] or established 
vascular disease, are more likely to self-report CKD. 
The primary aim of this study is to assess what factors (demographic, clinical and 
psychological) are associated with self-report of CKD. This will inform how information 
exchange around CKD in primary care could be tailored to diverse patient populations. It 
builds on work conducted within the NIHR CLAHRC (Collaboration for Leadership in 
Applied Health Research and Care) for Greater Manchester, which is a coordinated 
programme of research that aims to create, adapt and implement strategies to support socially 
disadvantaged people with long-term vascular conditions. 
Methods 
The trial has received full ethical approval from the Health Research Authority (REC 
reference: 11/NW0855) and is being conducted in accordance with the UK Department of 
Health’s Research Governance Framework. 
Participants and recruitment 
CKD is classified into five stages from stage 1 (mild) to stage 5 (established renal failure or 
end stage renal disease) based on estimated glomerular filtration rate (eGFR) [1,2,20]. Stages 
3 to 5 may be defined by a reduction in eGFR alone, though for stages 1 and 2, other markers 
of kidney damage are required for a diagnosis of CKD [1,2,6]. Recognising evidence of 
‘increased risk of mortality with an eGFR <45 ml/min/1.73 m2 in all age groups, stage 3 
CKD is split into two subcategories (3a and 3b) [1,2]. In addition, proteinuria (presence of 
excess protein in the urine) is also an independent predictor of mortality [21]. 
A total of 24 GP practices in the Greater Manchester area agreed to take part in an RCT 
evaluating a self-management intervention for vascular health in patients with stage 3 CKD 
[22]. Respecting GP judgement on eligibility, 440 out of 637 (69%) patients who agreed to be 
contacted were recruited between April and November 2012 with an average number of 16 
patients per practice (range: 3–44). Four patients were excluded post-randomisation found to 
not meet the criteria of stage 3 CKD. Data on the total number of patients approached to take 
part was very patchy making it not possible to determine the overall response rate. 
Thirteen GP practices had previously participated in an NIHR CLAHRC Renal Collaborative, 
which aimed to improve identification and management of CKD [23]. Inclusion criteria were 
a diagnosis of stage 3 CKD (stage 3a or 3b) as recorded on the general practice’s CKD 
register (a record of patients aged 18 years and over with stage 3–5 CKD which informs the 
UK’s pay-for-performance contract (QOF)). Efforts were made to ensure that patients had 
recently (ideally within the previous 6–8 weeks) attended their GP practice for a routine 
disease review appointment where their blood pressure had been taken and sign an informed 
consent form at the baseline assessment visit. Participants who were unable to communicate 
in English, lacked capacity to provide informed consent, or were in receipt of palliative care 
were excluded. Only one person per household was eligible to take part, to avoid potential 
contamination across trial arms. Detailed methods are reported in the trial protocol [22]. 
Data collection 
Baseline assessments were conducted within 6–8 weeks of a clinical appointment in primary 
care where baseline blood pressure was taken (Mean = 27.1 days prior to randomisation). 
Stage of CKD (3a and 3b) and evidence of proteinuria were also collected from general 
practice records. Patients completed a study questionnaire as part of the baseline assessment. 
This included the question ‘Please tell us if you have any of the following long-term medical 
conditions’, with a list of 17 long-term conditions for the patient to tick all that applied and 
free-text space for any additional long-term conditions (See Additional file 1). Self-report of 
CKD was defined by a ‘yes’ response to ‘Kidney Problems’. For consistency, if patients 
asked for further clarification about what was meant by ‘kidney problems’, interviewers were 
instructed to ask ‘Has your GP or other health professional told you that you have problems 
with your kidneys?’ Interviewers were instructed to offer no further prompts to patients. 
Other variables collected at baseline included self-reported demographics (age, gender, 
ethnicity, level of education completed and deprivation), and information on co-morbid 
(additional to CKD) long-term conditions and vascular risk factors, as well as measures of 
disease self-management ability (heiQ; [24]), health status (SF36; [25]) health related quality 
of life (EuroQol EQ-5D; [26]), anxiety (HADS-A; [27]), and health service utilisation. 
Further details of these measures are available in the trial protocol [22]. 
Statistical analysis 
Continuous variables were summarised using means and standard deviations (SDs), and 
categorical data with counts and percentages. Rates of missing data were low (<5% for all 
variables) and Expectation-Maximisation (EM) imputation was applied to impute missing 
values using the full set of baseline variables. Imputation and analyses were conducted using 
STATA IC (version 12.1) with an alpha level for significance of 5%. General practice was 
defined as a random effect in all the models and robust estimates of variance were used. The 
main trial was not powered for an analysis of CKD self-report predictors. However, post-hoc 
power analysis indicated that the sample of 436 with a 48% self-report rate, had 90% power 
to detect an odds-ratio of 1.38 between an explanatory factor and CKD self-report at 
alpha=5%. For a two-level predictor, this equates to an 8% difference between levels (i.e. 
52% v 44%). 
In order to investigate what factors were associated with self-reporting of CKD, univariate 
logistic regression with patients clustered by practice was used to explore the association 
between each explanatory variable and self-report of CKD. Multivariate logistic regression 
analysis was next applied using all variables from the univariate analyses with p values <=0.1 
(to avoid prematurely excluding important associations) as predictors to identify independent 
predictors of self-report of CKD. A backwards elimination procedure was used to 
sequentially remove predictors with the highest p values until all remaining variables were 
significant at the p < 0.05 level. Predictor variables with more than two categories were 
modelled using sets of indicator variables. We used variance inflation factors (VIFs) to 
examine possible collinearity between explanatory variables. 
To calculate overall predictive power for the logistic regression models we used the 
McKelvey and Zavoina R2, which estimates explained variance in a latent continuous 
variable underlying observed awareness (yes/no). We used this measure for ease of 
interpretation as it is comparable to explained variance in linear regression [28]. To assess if 
levels of CKD awareness differed between practices, we estimated the percentage of the total 
variance accounted for by differences between practices and compared this to zero using a 
likelihood-ratio chi-square test. We did this both with and without control for significant 
patient-level predictors of CKD self-report. 
Results 
Baseline data are summarised in Table 1. A total of 436 eligible patients from 24 GP 
practices (70.6% of the 34 practices approached) provided baseline data. Practices had a 
mean list size of 5815 patients and we recruited an average of 16 patients per practice (range 
3–44). 58.5% (n =255) were female and patients were almost all of white ethnicity. The mean 
age of patients was 72.1 years. Patients reported a mean number of co-morbid long-term 
conditions (excluding kidney problems) of 3.5 (from the other 16 conditions listed and any 
additional long-term conditions reported in the free-text). 41.7% (n =182) of patients had co-
morbid established cardiovascular disease. 
Table 1 Baseline characteristics 
 Total (n =436) Did not self-report kidney 
problems (n = 227) 
Self-reported kidney 
problems (n = 209) 
Odds-ratio 
(95% CI) 
Univariate 
 P-Value 
Recruited from collaborative practice    1.18 (0.78, 
1.80) 
0.43 
    No 174 (39.9) 95 (54.6) 79 (45.4)   
    Yes 262 (60.1) 132 (50.4) 130 (49.6)   
Gender    1.69 (1.14, 
2.50) 
0.009** 
    Male 181 (41.5) 108 (59.7) 73 (40.3)   
    Female 255 (58.5) 119 (46.7) 136 (53.3)   
Age     0.24 
    <70 157 (36.0) 75 (47.8) 82 (52.2) 1.0  
    70-79 178 (40.8) 95 (53.4) 83 (46.6) 0.80 (0.61, 
1.05) 
 
    80+ 101 (23.2) 57 (56.4) 44 (43.6) 0.71 (0.39, 
1.29) 
 
Ethnicity    5.54 (0.53, 
57.81) 
0.15 
    White 430 (98.6) 226 (52.6) 204 (47.4)   
    Non-white 6 (1.4) 1 (16.7) 5 (83.3)   
Education    1.04 (0.70, 
1.55) 
0.85 
    No qualifications 192 (44.0) 101 (52.6) 91 (47.4)   
    > = 1 qualification 244 (56.0) 126 (51.6) 118 (48.4)   
Index of multiple deprivation (IMD) (Higher score = greater deprivation) 16.95 (9.8, 31.7) 16.16 (9.6, 31.1) 18 (10.1, 31.7) 1.00 (0.99, 
1.02) 
0.55 
Access internet for health information    1.23 (0.74, 
2.05) 
0.43 
    No 322 (73.9) 172 (53.4) 150 (46.6)   
    Yes 114 (26.1) 55 (48.3) 59 (51.8)   
CKD stage    2.67 (1.96, 
3.64) 
<0.001*** 
    3a 330 (75.7) 191 (57.9) 139 (42.1)   
    3b 106(24.3) 36 (34.0) 70 (66.0)   
Proteinuria    1.95 (1.02, 
3.69) 
0.042* 
    No 388 (89.0) 209 (53.9) 179 (46.1)   
    Yes 48 (11.0) 18 (37.5) 30 (62.5)   
Co-morbid long-term conditions     0.020* 
    <=2 136 (31.2) 79 (58.1) 57 (41.9) 1.0  
    3 or 4 192 (44.0) 100 (52.1) 92 (47.9) 1.28 (0.84, 
1.94) 
 
    5+ 108 (24.8) 48 (44.4) 60 (55.6) 1.73 (1.17, 
2.57) 
 
Co-morbid established cardiovascular disease    1.11 (0.89, 
1.39) 
0.36 
    No 254 (58.3) 135 (53.2) 119 (46.9)   
    Yes 182 (41.7) 92 (50.6) 90 (49.5)   
High blood pressure    0.91 (0.62, 
1.33) 
0.61 
    No 174 (39.9) 88 (50.6) 86 (49.4)   
    Yes 262 (60.1) 139 (53.1) 123 (47.0)   
Prostate and urological problems    1.15 (0.61, 
2.18) 
0.67 
    No 387 (88.8) 203 (52.5) 184 (47.6)   
    Yes 49 (11.2) 24 (49.0) 25 (51.0)   
Diabetes    0.84 (0.55, 
1.28) 
0.41 
    No 335 (76.8) 171 (51.0) 164 (49.0)   
    Yes 101 (23.2) 56 (55.5) 45 (44.6)   
Arthritis or painful joints, back trouble, osteoporosis    1.38 (0.82, 
2.33) 
0.23 
    No 150 (34.4) 86 (57.3) 64 (42.7)   
    Yes 286 (65.6) 141 (49.3) 145 (50.7)   
≥1 Other (COPD, stomach ulcer, reflux or IBS, CFS, neurological 
condition, thyroid problems, skin problems, cancer, haematology, ENT, eye 
problems or dementia). 
   1.34 (0.95, 
1.90) 
0.094 
    No 166 (38.1) 94 (56.6) 72 (43.4)   
    Yes 270 (61.9) 133 (49.3) 137 (50.7)   
General health (Higher score = better general health) 2.75 ± 0.94 2.89 ± 0.96 2.60 ± 0.90 0.72 (0.60, 
0.85) 
<0.001*** 
Energy & Vitality (Higher score = greater energy levels) 50.78 ± 22.83 55.39 ± 21.65 45.77 ± 23.07 0.98 (0.97, 
0.99) 
<0.001*** 
HADS –anxiety     <0.001*** 
    0-3 183 (42.0) 107 (58.5) 76 (41.5) 1  
    4-7 151 (34.6) 86 (57.0) 65 (43.1) 1.06 (0.61, 
1.86) 
 
    8+ 102 (23.4) 34 (33.3) 68 (66.7) 2.82 (1.46, 
5.43) 
 
SCDSC self-care (Higher score = greater self-care skills) 4.35 ± 1.23 4.40 ± 1.24 4.29 ± 1.21 0.93 (0.85, 
1.02) 
0.13 
> 1 cardiovascular risk factor (Diabetes, hypertension or smoking)    1.18 (0.78, 
1.77) 
0.44 
    No 352 (80.7) 186 (52.8) 166 (47.2)   
    Yes 84 (19.3) 41 (48.8) 43 (51.2)   
HeiQ (Self-monitoring and insight) (Higher score = greater self-monitoring) 68.97 ± 12.26 70.74 ± 11.61 67.05 ± 12.68 0.97 (0.96, 
0.99) 
0.002** 
HeiQ (Health services navigation) (Higher score = greater health service 
navigation) 
69.67 ± 15.29 71.31 ± 15.05 67.9 ± 15.39 0.99 (0.97, 
1.00) 
0.01* 
GP contact in previous 6 months 2 (1, 4) 2 (1, 3) 2 (1, 4) 1.07 (1.01, 
1.14) 
0.027* 
Nurse visits in previous 6 months 2 (1, 3) 2 (1, 3) 2 (1, 3) 1.03 (0.98, 
1.09) 
0.29 
Total hospital visits in previous 6 months 1 (0, 2) 0 (0, 2) 1 (0, 2) 1.03 (0.99, 
1.06) 
0.12 
Data are mean ± SD, number (%) or median (25th, 75th percentile) when data are skewed. Patients aware of kidney problems versus those not 
aware. * ==p < 0.05, **== p < 0.01, *** = p < 0.001. 
Just over half of patients (52.1%, n = 227) did not self-report CKD. Rates of self-report 
varied between practices, from a low of 22.7% (5 out of 22 patients) to a high of 75% (3 out 
of 4 patients). 
In univariate analysis, patients who self-reported CKD were significantly (p < 0.05) more 
likely to be female, have CKD stage 3b, have proteinuria, poorer self-reported general health, 
lower energy and vitality, higher levels of general anxiety, lower levels of self-monitoring 
and insight (heiQ; [24]), poorer health services navigation skills (heiQ; [24]), and more 
frequent contact with their GP (see OR’s in Table 1). Patients with greater numbers of long-
term conditions were also more likely to self-report CKD. However, age, socioeconomic 
status, cardiovascular risk factors and established cardiovascular disease, did not show 
significant relationships with self-report of CKD (p > 0.05). There was no significant 
difference in self-report of CKD between patients recruited from CLAHRC collaborative and 
non-collaborative practices [23]. 
Variance inflation factors amongst the explanatory variables entered into the multivariate 
analysis were all low (maximum =2.3), indicating acceptable multicollinearity [29]. Since 
both stage of CKD and proteinuria were potential explanatory variables, we also added their 
interaction term to the initial model. In multivariate analysis, just three variables remained in 
the model as independent predictors of self-report of CKD: stage of CKD, gender and 
anxiety. Women were more likely to self-report CKD than men (OR = 1.68, 95% CI 1.18-
2.39). The relationship with anxiety was nonlinear: patients with low levels of anxiety 
(HADS <=3) and moderate anxiety scores (HADS =4 to 7) had very similar degrees of 
awareness, but patients with clinical levels of anxiety (HADS >=8) were much more likely to 
show awareness (OR = 2.83, 95% CI 1.44-5.54) compared to low anxiety. The association 
with stage of CKD indicated considerably higher levels of self-report amongst patients at 
stage 3b compared to stage 3a (OR = 2.94, 95% CI 2.16-4.01) (See Table 2). Subgroup 
differences are illustrated in Figures 1, 2 and 3. The model as a whole explained 
approximately 13% of the variance in patient awareness (McKelvey and Zavoina’s R2 = .13). 
Table 2 Multivariate analysis of awareness of kidney problems 
Variable Odds-ratio (95% CI) P-Value 
Gender - Female 1.68 (1.18, 2.39) 0.004** 
HADS – Anxiety  <0.001*** 
    0- 3 1  
    4-7 0.95 (0.56,1.61)  
    8+ 2.83 (1.44, 5.54)  
CKD Stage 3b 2.94 (2.16, 4.01) <0.001*** 
**== p < 0.01, ***==p < 0.001. 
Figure 1 Bar graph indicating the percentage1 of patients reporting kidney problems by 
gender. 1Percentages controlled for other significant predictors (CKD stage and HADS-
anxiety). 
Figure 2 Bar graph indicating the percentage1 of patients reporting kidney problems by 
CKD stage. 1Percentages controlled for other significant predictors (gender and HADS-
anxiety) 
Figure 3 Bar graph indicating the percentage1 of patients reporting kidney problems by 
HADS-Anxiety score. 1Percentages controlled for other significant predictors (gender and 
CKD stage). 
Both with and without control for these patient factors, the percentage of total variance 
accounted for by differences in levels of CKD awareness between practices was very low, 
less than 1%, and not statistically significant (p = 0.49 and p = 0.41, respectively). 
Discussion 
An analysis of baseline data from 436 patients with a diagnosis of CKD stage 3 from an RCT 
[22] was conducted. Patients were elderly (64% of patients were aged over 70 years) and had 
relatively high numbers of additional long-term conditions. Despite being recruited from a 
CKD register, around half of all patients did not self-report CKD. 
Self-report of CKD did not appreciably differ between individual practices, or between 
CLAHRC Renal Collaborative practices and non-collaborative practices, suggesting that 
patient level characteristics may be more important in predicting self-report of CKD than 
practice level differences. Patients who were female and those with CKD stage 3b, were 
significantly more likely to self-report CKD. Using a criteria of a HADS anxiety score of 8 or 
more to indicate anxiety above normal levels [30,31], the large majority of patients (n =334, 
76.6%) fell within a normal range of anxiety symptoms. However, despite this, patients with 
above normal HADS anxiety scores were significantly more likely to self-report CKD. 
Comparison with existing literature 
Our findings are consistent with previous research which has shown that awareness of early 
stage CKD is variable [8,16], clinical discussion about CKD infrequent [9], and use of the 
QOF registers for CKD inconsistent [6]. The findings may reflect wider issues around the 
merits of discussing early stage CKD with patients who are often elderly and multimorbid, 
with concerns of unnecessary ‘disease labelling’ [2,16,17,19,32]. Nevertheless, evidence 
suggests that patients, regardless of age, expect to be informed about diagnostic information 
[33] and our findings suggest that procedures to meet this expectation may be variable and 
inconsistent. 
Patients with stage 3b CKD were significantly more likely to self-report CKD than stage 3a 
patients which is consistent with evidence of controversy about the benefits of discussing 
CKD with patients, particularly those who have stage 3a CKD [15,19,32]. It may be that 
conversations about CKD with stage 3a patients are framed as reassurance [19] and thus 
provide ambiguous understanding and inconsistent knowledge of the relevance of CKD to 
patients overall health. Recognising the importance of monitoring for disease progression, 
future research would benefit from identifying whether patients with declining (versus stable) 
renal function are more or less likely to self-report CKD. 
Previous research suggests that younger, male patients are more likely to be aware of CKD 
than older female patients [8,16]. However, a substantially higher percentage of females in 
our sample self-reported CKD compared to males, and we did not find age a significant 
predictor of self-report. Our elderly sample included few patients under 65 years, which may 
help explain why we did not find that self-report of CKD decreased significantly with 
increasing age as expected. 
In contrast to previous US-based studies [7,16] we did not find established vascular disease 
or risk factors including diabetes to be significantly associated with self-reporting of CKD. 
Our results were similar to a recent UK-based study [8] and may suggest that conversations 
with health-care professionals around vascular health could be seen as somewhat separate 
from conversations around CKD. 
Strengths and limitations 
The inclusion criteria (patient on a CKD register and attendance at a recent disease review 
appointment) ensured that all patients in our sample were diagnosed with stage 3 CKD and 
were being actively managed in primary care. 
However, the use of baseline data from a trial leads to certain limitations. Samples 
participating in trials in primary care are generally atypical. Over two thirds of eligible 
patients participated, but we were unable to assess non-response as accurate data on the total 
number of patients approached were not available, and we cannot make strong statements 
about awareness in the wider population based on such a sample. However, the focus of the 
study was on associations between patient and practice characteristics and self-report of 
CKD. Such associations are less likely to be affected by low proportions of patients taking 
part in a trial, although appropriate caution must be exercised in making generalisations. 
The validity of the analyses is dependent on the validity of the measures used. We recognise 
that patient self-reporting of CKD in terms of ‘kidney problems’ does not necessarily equate 
with lack of clinical dialogue. Previous research has highlighted that discussions around CKD 
by GPs and practice nurses with patients are often normalised and framed in the form of 
reassurance [19], for example by framing deterioration of kidney function as a normal 
consequence of ageing, thereby perhaps decreasing the likelihood that patients self-report 
CKD. Observational analysis is needed to illuminate the framing of CKD during clinical 
encounters [34]. Nevertheless, our results are comparable to a previous study by McIntyre et 
al. [8] who utilised a similar self-report measure and found that 41% of patients with stage 3 
CKD were unaware of their diagnosis. Further research is required to capture more detailed 
accounts of patients knowledge not only of CKD but also awareness around self-
management. 
Due to the cross-sectional nature of this study, we have to be cautious when interpreting the 
direction of the relationship between anxiety levels and self-report of CKD. Although the 
majority of patients were within the normal range of anxiety symptoms, those who reported 
higher levels of anxiety were more likely to be aware of kidney problems. Three potential 
explanations for why anxiety may be significantly higher in patients that self-report CKD 
include, a) receiving a CKD diagnosis increases anxiety, b) anxiety promotes information-
seeking and active communication with a healthcare professional about CKD, or c) anxiety 
inflates the likelihood that patients self-report conditions in general, including CKD. 
However, not all patients with higher levels of anxiety reported kidney problems. This might 
be indicative of a reassuring conversation around kidney health due to healthcare 
professionals sensitivity to the patient’s anxiety. Further research will be required in order to 
clarify these relationships. 
The BRIGHT trial recruited patients with a diagnosis of stage 3 CKD but did not collect data 
on evidence of a rate of decline in renal function (eGFR of >5 ml/min/1.73 m2 within 1 year, 
or >10 ml/min/1.73 m2 within 5 years) [1]. Although data was collected on staging (3a or 3b) 
and evidence of proteinuria, we acknowledge that the study was unable determine whether 
patients with evidence of disease progression are more or less likely to self-report CKD. 
Implications 
Despite efforts to improve the identification of stage 3 CKD in primary care, over half of the 
patients recruited from a CKD register as part of a wider RCT, did not self-report CKD. The 
low levels of reporting of CKD raises issues around the optimisation of interventions and trial 
designs in this population [35]. Although efforts were made to build on existing clinical 
practice, these findings from baseline analysis, irrespective of final trial outcomes, suggest 
that information resources to support understanding of CKD and the maintenance of vascular 
health may benefit from closer alignment with existing clinical encounters. 
Our data suggests the need for greater consistency in discussions around kidney health. 
Broadening and tailoring the scope of a CKD diagnosis by framing it in the context of 
patient’s overall health may assist practitioners in ensuring meaningful and relevant 
conversations about kidney health, which are aligned with existing clinical encounters such 
as cardiovascular disease reviews, medication reviews and prevention of acute kidney injury 
(AKI) during phases of acute illness (e.g. sepsis due to flu). Recently published guidelines on 
the prevention, detection and management of AKI may support this shift in clinical dialogue 
and assist with shared decision making [36]. As recommended by NICE, patient involvement 
in research is required in order to support the development and communication of more 
personalised information around the management of CKD [1]. 
Conclusions 
Our data indicates that patient self-report of CKD is variable, suggesting a need for greater 
consistency in discussions around kidney health. In light of our findings and recent research 
and commentary highlighting a need for effective strategies to improve the management of 
CKD and prevention of AKI [8,32,37-39], we argue that information exchange concerning 
early stage CKD may be improved by broadening the reasons for communication. Further 
patient-orientated research is needed to support the development and tailoring of information 
to ensure maintenance of kidney health, whilst minimising health burden and anxiety. 
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